Nausea:
Indications for: APONVIE
Prevention of postoperative nausea and vomiting (PONV).
Limitations of Use:
Not for treating established nausea and vomiting.
Adult Dosage:
Give prior to induction of anesthesia. 32mg IV over 30secs. Flush with normal saline prior to and after administration.
Children Dosage:
Not established.
APONVIE Contraindications:
Concomitant pimozide.
APONVIE Warnings/Precautions:
Monitor for hypersensitivity reactions; discontinue and treat appropriately if occur; do not reinitiate if symptoms developed with previous use. Severe hepatic impairment. Pregnancy: avoid. Advise females of reproductive potential using hormonal contraceptives to use an effective alternative or back-up non-hormonal contraception for 1 month after administration. Nursing mothers.
APONVIE Classification:
Substance P/NK1 receptor antagonist.
APONVIE Interactions:
See Contraindications. Avoid concomitant strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) or strong CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin). May antagonize warfarin (closely monitor INR for 2 weeks after starting each cycle), other CYP2C9 substrates, oral contraceptives (use alternative or backup methods [eg, condoms, spermicides]).
Adverse Reactions:
Constipation, fatigue, headache.
Drug Elimination:
Half-life: 12 hours. Mean plasma clearance: 4.4 L/h.
Generic Drug Availability:
NO
How Supplied:
Single-dose vials—10
